ResearcherTrinity College DublinActive in the last 2 years

Jojanneke Stoof

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8331-1597; OpenAlex author ID A5016982974. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 4

Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer. Co-author DOI 10.1016/j.biopha.2026.119273 ↗
CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. First author DOI 10.1016/j.semcancer.2025.07.004 ↗
Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/jcmm.70816 ↗
DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Co-author DOI 10.3389/fcell.2021.749490 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Naomi Walsh · 4 shared papers, 2021–2026 · strength 1.02
Maeve Aine Lowery · 2 shared papers, 2021–2025 · strength 0.47
- Paper Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma. DOI 10.1111/jcmm.70816 ↗
- Paper DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. DOI 10.3389/fcell.2021.749490 ↗
Sara Noorani · 1 shared paper, 2026 · strength 0.30
- Paper Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer. DOI 10.1016/j.biopha.2026.119273 ↗
Paula Meleady · 1 shared paper, 2026 · strength 0.30
- Paper Fatty Acid Synthase (FASN) as a targeted therapeutic in acquired 5-fluorouracil resistance in pancreatic cancer. DOI 10.1016/j.biopha.2026.119273 ↗
Yanxi Lu · 1 shared paper, 2025 · strength 0.25
- Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004 ↗
Jelena Grahovac · 1 shared paper, 2025 · strength 0.25
- Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004 ↗
Robert Grützmann · 1 shared paper, 2025 · strength 0.25
- Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004 ↗
Tianhui Chen · 1 shared paper, 2025 · strength 0.25
- Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004 ↗
Christian P. Pilarsky · 1 shared paper, 2025 · strength 0.25
- Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004 ↗
Maarten F. Bijlsma · 1 shared paper, 2025 · strength 0.25
- Paper CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. DOI 10.1016/j.semcancer.2025.07.004 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.